Literature DB >> 22527213

[Immune reconstitution syndrome].

D Meyer-Olson1, D Ernst, M Stoll.   

Abstract

The immune reconstitution inflammatory syndrome (IRIS) represents a heterogeneous group of conditions. Whilst they typically present in HIV-infected patients with advanced immunodeficiency, IRIS have also been described in HIV-negative patients with immune reconstitution due to other causes of immunosuppression. Frequently IRIS results from an immune response against underlying infection (pathogen-associated IRIS). However, IRIS might become evident during immune reconstitution without an underlying pathogen such as a sarcoid-like illness or an autoimmune thyropathy. Here we report on the epidemiology and risk factors of IRIS along with diagnosis and management of this clinically important inflammatory syndrome.

Entities:  

Mesh:

Year:  2012        PMID: 22527213     DOI: 10.1007/s00393-011-0858-7

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  128 in total

1.  Immunorestitution diseases in patients not infected with HIV.

Authors:  V C Cheng; K Y Yuen; S S Wong; P C Woo; P L Ho; R Lee; R M Chan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2001-06       Impact factor: 3.267

2.  Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy.

Authors:  Juan Berenguer; Pilar Miralles; Julio Arrizabalaga; Esteban Ribera; Fernando Dronda; Josu Baraia-Etxaburu; Pere Domingo; Manuel Márquez; Francisco J Rodriguez-Arrondo; Fernando Laguna; Rafael Rubio; José Lacruz Rodrigo; J Mallolas; Verónica de Miguel
Journal:  Clin Infect Dis       Date:  2003-04-02       Impact factor: 9.079

Review 3.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

4.  Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab.

Authors:  Robert Belknap; Randall Reves; William Burman
Journal:  Int J Tuberc Lung Dis       Date:  2005-09       Impact factor: 2.373

Review 5.  Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of disease.

Authors:  Leonard H Calabrese; Elizabeth Kirchner; Rabin Shrestha
Journal:  Semin Arthritis Rheum       Date:  2005-12       Impact factor: 5.532

6.  The economy of inflammation: when is less more?

Authors:  Brittany F Sears; Jason R Rohr; Judith E Allen; Lynn B Martin
Journal:  Trends Parasitol       Date:  2011-06-15

Review 7.  Biomarkers in immune reconstitution inflammatory syndrome: signals from pathogenesis.

Authors:  Irini Sereti; Alison J Rodger; Martyn A French
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

8.  Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy.

Authors:  Julian H Elliott; Khol Vohith; Sarun Saramony; Chin Savuth; Chan Dara; Chel Sarim; Sarah Huffam; Robert Oelrichs; Pouv Sophea; Vonthanak Saphonn; John Kaldor; David A Cooper; Mean Chhi Vun; Martyn A French
Journal:  J Infect Dis       Date:  2009-12-01       Impact factor: 5.226

Review 9.  Immune reconstitution inflammatory syndrome: immunopathogenesis, risk factors, diagnosis, treatment and prevention.

Authors:  S J E Beishuizen; S E Geerlings
Journal:  Neth J Med       Date:  2009-11       Impact factor: 1.422

10.  Paradoxical response during antituberculous therapy in a patient discontinuing infliximab: a case report.

Authors:  Young Kyung Yoon; Jeong Yeon Kim; Jang Wook Sohn; Min Ja Kim; Ja Seol Koo; Jai Hyun Choi; Dae Won Park
Journal:  J Med Case Rep       Date:  2009-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.